Category: The Evidence
Nootropic is a marketing word covering an enormous evidence gradient. Caffeine is the best-supported and most boring; the caffeine and l-theanine combination has modest real support; ginkgo and ginseng mostly disappoint in their best trials; bacopa is real but slow.
Category: Research Reviews | Reading time: ~13 min | Level: Intermediate
Nootropic is a marketing word before it is a scientific one. It describes an enormous, deliberately loose category: capsules promising sharper memory, better focus, or vague "cognitive enhancement," lined up on the same shelf as though the evidence behind each ingredient were roughly comparable. It is not. Line up the actual trials and the category turns out to hold a steep gradient, from a substance so ordinary that almost nobody thinks to call it a nootropic, to herbal traditions whose largest, best-conducted trials have come back flatly negative.
That gradient is the whole story worth telling here. A supplement aisle organised by marketing puts a ginkgo capsule next to a caffeine and l-theanine blend next to a bacopa extract, all under one reassuring word, implying similar scientific backing. Organised by evidence, it looks completely different: caffeine near the top, the caffeine and l-theanine pairing not far behind, bacopa in the middle with an asterisk about patience, and ginkgo trailing well behind its own marketing. This review builds that second, honest ordering.
One boundary first. Racetams and modafinil, sometimes discussed alongside natural nootropics, are prescription or unregulated pharmaceutical substances, not supplements, and this review does not assess them.
Here is the short version. Caffeine has the best-substantiated cognitive effects of any common nootropic substance, specifically for alertness and attention, and paired with l-theanine it shows moderate, real evidence for improved attention-switching and vigilance [1][2]. L-theanine alone is weaker, and EU regulators have twice judged the standalone evidence insufficient [4]. Ginkgo biloba failed the largest, longest trial ever run on it [5], and a Cochrane review calls the wider evidence inconsistent and unreliable [6]. Ginseng shows a narrow memory-specific signal but no broader cognitive benefit [7][8]. Bacopa monnieri has real but slow-developing memory evidence, typically taking around twelve weeks [9][10].
The word "nootropic" was coined in the 1970s to describe substances thought to enhance cognition with minimal side effects, and it has since been stretched to cover almost anything marketed for memory, focus or mental performance, regardless of how it works or how well it has been studied. That looseness is the central problem with the category as sold today.
The ingredients grouped under this one label work through entirely unrelated mechanisms: caffeine blocks a receptor for a fatigue-signalling molecule, l-theanine appears to modulate brain activity associated with relaxed alertness, ginkgo is proposed to affect blood flow and antioxidant activity via flavonoids, ginseng is studied for compounds called ginsenosides, and bacopa is thought to act on memory formation over weeks of use. Grouping substances this different under one marketing word invites the assumption that if one nootropic works, the rest probably do too, which the evidence below does not support.
Start with the ingredient nobody markets as exciting, because it is the one with the clearest support. The European regulatory assessment of caffeine describes it as having the best-substantiated cognitive effects among commonly used nootropic substances, specifically for alertness, attention and vigilance, and explicitly not for memory or general intelligence [1]. That is a narrower claim than "boosts brainpower," and a more honest one than most products manage.
The assessment also notes that tolerance develops with regular caffeine use, meaning the same dose produces a smaller alertness effect over time. Caffeine remains, by a clear margin, the best-evidenced substance in this review. It is simply too familiar and too cheap to be marketed as a premium nootropic, which says more about marketing incentives than about the science.
The next tier down, and still genuinely defensible, is the caffeine and l-theanine combination. A systematic review and meta-analysis by Payne and colleagues, covering fifty randomised controlled trials and pooling results from fifteen, found the combination improved attention-switching accuracy and digit-vigilance accuracy versus placebo, with l-theanine alone producing a smaller improvement in choice reaction time [2]. The authors flagged wide confidence intervals, an honest signal that the true size of the benefit is uncertain even though its direction looks consistent.
A separate, more recent review by Gerolymos and colleagues, covering thirty-one trials and more than a thousand participants, examined l-theanine given alone rather than with caffeine, and found that a single 200mg dose improved attention, again measured by choice reaction time, with a moderate effect size [3]. The same analysis found stress reduction was modest and largely driven by studies with a higher risk of bias, found no effect on fatigue, and reported no serious adverse events, a reassuring safety signal even where the cognitive benefit is modest.
Honest evidence grade for caffeine plus l-theanine: moderate. Two independent lines of meta-analytic evidence point the same direction on attention, the effect sizes are real but not large, and the combination is safe at the doses studied.
Separated from caffeine, l-theanine's case weakens. The European Food Safety Authority has assessed isolated l-theanine twice, in 2011 and again in 2018, and both times concluded that cause and effect had not been established between l-theanine alone and improved cognition, stress or sleep [4]. Where black tea has been shown to support attention, the regulator attributed that benefit to the caffeine in the tea, not the theanine [4], quietly undercutting one of the more commonly cited pieces of evidence for theanine's standalone effects.
This does not erase the modest attention signal found in the Gerolymos meta-analysis for a single 200mg dose taken alone [3]. A regulator specifically tasked with scepticism has twice declined to endorse l-theanine on its own, while newer pooled trial evidence finds a real if modest attention effect. Honest evidence grade for l-theanine alone: limited.
Ginkgo biloba is one of the oldest and most heavily marketed cognitive herbs, and also the ingredient here with the most damning best-case evidence. The Ginkgo Evaluation of Memory trial, known as GEM, followed 3,069 adults aged seventy-five and older for a median of 6.1 years, the largest and longest ginkgo trial ever conducted, and found that 120mg of ginkgo twice daily did not reduce dementia incidence versus placebo [5]. It was purpose-built, at considerable scale, to answer exactly the question ginkgo is sold on, and it answered no.
A Cochrane review by Birks and Grimley Evans, examining thirty-six trials of ginkgo for cognitive impairment and dementia, reached a similarly sobering conclusion: the evidence that ginkgo produces predictable, clinically significant benefit for cognition is inconsistent and unreliable [6]. NCCIH's fact sheet is equally blunt, stating there is no conclusive evidence that ginkgo is helpful for any health condition [11].
Honest evidence grade for ginkgo biloba: limited to negative. This is the clearest case here of an ingredient's marketing reputation outrunning its best available evidence.
Ginseng's evidence is more nuanced than ginkgo's, but still falls short of its marketing. A Cochrane review by Geng and colleagues concluded there was a lack of convincing evidence that Panax ginseng enhances cognition in healthy people [7], a broad, unambiguous negative from a rigorous review body.
A more recent meta-analysis by Zeng and colleagues, covering fifteen randomised controlled trials and 671 patients, found a narrower picture: ginseng showed a significant effect on memory, with a modest effect size, but no benefit for overall cognition, attention or executive function [8]. That is a more defensible claim than "ginseng sharpens the mind." NCCIH notes ginseng is registered mainly on traditional use rather than strong trial evidence, and flags insomnia and hypoglycaemia, particularly relevant alongside diabetes medication [11].
Honest evidence grade for ginseng: limited, memory-only signal. The Zeng meta-analysis reads as genuinely promising for memory specifically, while Cochrane's broader "improves cognition" verdict remains a no.
Bacopa monnieri is the one herbal ingredient here with a defensible, if heavily caveated, case. A systematic review by Pase and colleagues found that it improved memory acquisition and delayed recall across the trials examined, but noted these effects consistently took around twelve weeks to appear [9]. A later meta-analysis by Kongkeaw and colleagues similarly found bacopa improved some memory measures, while flagging small, inconsistent trials and common gastrointestinal side effects [10].
The pattern across both reviews is the honest headline: bacopa is not a same-day or same-week cognitive booster, and anyone taking it expecting an immediate effect is likely to conclude, wrongly, that it does not work. Its evidence is also thinner in absolute terms than the caffeine and l-theanine literature, resting on fewer, smaller trials.
Honest evidence grade for bacopa monnieri: limited but real, and slow. Among the herbal ingredients reviewed here, it has the most credible memory-specific signal, provided expectations are set around a twelve-week timeline.
These belong to a different category entirely and sit outside this review by design. Racetams are largely unregulated as supplements in some markets while being prescription medicines in others, and modafinil is a prescription wakefulness-promoting medication. Neither has the over-the-counter safety and efficacy evidence base this review is built to assess. That conversation belongs with a doctor, not a supplement guide.
Grade your expectations to match the evidence, ingredient by ingredient, rather than trusting the word "nootropic" to do that work for you. If your goal is alertness and attention, caffeine remains the most reliably effective option, and pairing it with l-theanine, roughly 40mg of caffeine with around 100mg of l-theanine or higher, adds a modest, real benefit without much additional downside.
If you are drawn to ginkgo on reputation, know its largest and longest trial found no dementia-prevention benefit. If ginseng interests you, hold the claim to what recent evidence shows, a modest memory-specific effect, not a general cognitive boost, and note the insomnia and hypoglycaemia cautions. If you are considering bacopa, commit to a genuine twelve-week trial before judging it.
Resist stacking multiple bioactive ingredients at once hoping more nootropics means more effect. Each ingredient here carries its own caution, and combining several increases the interactions you are exposed to without a corresponding increase in evidence that the stack works better than its best single component.
Caffeine. Generally safe for most healthy adults within established daily limits, but it disrupts sleep when taken late in the day and produces tolerance with regular use.
Ginkgo biloba. Carries a real, if rare, bleeding risk, and should be stopped before surgery; it can also interact with blood-thinning medication.
Ginseng. Associated with insomnia in some users and carries a hypoglycaemia caution, particularly relevant for anyone on diabetes medication, where the combined blood sugar effect needs medical oversight.
Bacopa monnieri. Gastrointestinal side effects are commonly reported in trials, and its slow onset means side effects may need to be tolerated for weeks before any benefit appears.
Interaction caution generally. Several of these ingredients interact with prescribed medications, including blood thinners and diabetes medication, and these interactions are documented in the published literature on each ingredient; anyone on regular medication should check the specific ingredient against their prescriptions before starting.
Pregnant, breastfeeding, or on medication? Check with a healthcare professional first.
We would rather grade each of these ingredients honestly than let one flattering word cover for all of them. Caffeine earns its reputation; the caffeine and l-theanine pairing earns a more modest but real one; ginkgo does not earn the reputation it has; ginseng earns a narrower claim than it is usually sold on; bacopa earns patience rather than hype. That is the standard we hold every ingredient in our Remedy Library to, cognition included.
Where stress is tangled up with focus and mental fatigue, an ashwagandha stress tonic sits in our library with the same structure and function framing used throughout this review, offered as a traditional support for feeling less wound up, not a cognitive enhancer. If you want a specific ingredient checked against your own medications, Remy can walk through the safety notes in more detail than any single article can hold.
The honest state of nootropic science is less exciting than the marketing, and more useful. One ordinary stimulant does most of the real work. One pairing adds a modest, genuine boost on top of it. A handful of herbal traditions carry a narrower, slower signal than their reputations suggest, and at least one has failed its own best test outright. None of that is a reason for cynicism about the category. It is a reason to read the evidence for each ingredient on its own terms, and to let the word "nootropic" describe a marketing shelf rather than a scientific one.
The questions above cover what people actually want to know when they ask whether nootropics work: which ingredients hold up, why caffeine outperforms most of its flashier competitors, why ginkgo's biggest trial was negative, what ginseng's narrower memory finding actually means, and why bacopa needs patience rather than a quick judgement. The short version: grade each ingredient on its own evidence, not on the word attached to the bottle.
1. European Food Safety Authority (EFSA). Scientific opinion on the safety of caffeine (2015). Regulatory scientific opinion. 2. Payne ER, et al. (2025). Effects of tea (Camellia sinensis) or its bioactive compounds l-theanine or l-theanine plus caffeine on cognition, sleep, and mood in healthy participants: a systematic review and meta-analysis. Nutrition Reviews. 2025;83(10):1873-1891. Fifty RCTs reviewed, 15 pooled; theanine plus caffeine favoured on attention-switching and digit-vigilance accuracy, theanine alone on choice reaction time, with wide confidence intervals. PMID 40314930. 3. Gerolymos C, et al. (2026). Cognitive and affective effects of L-theanine: a systematic review and meta-analysis of 31 randomized trials. Molecular Psychiatry. Systematic review and meta-analysis of 31 RCTs, n=1,168. doi 10.1038/s41380-026-03727-9. 4. European Food Safety Authority (EFSA). Scientific opinion on the substantiation of health claims related to l-theanine (EFSA Journal 2011;9(6):2238); and Black tea and improvement of attention: evaluation of a health claim (EFSA Journal 2018;16(5):5266). Regulatory scientific opinions. 5. DeKosky ST, et al. (2008). Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. RCT, n=3,069, median follow-up 6.1 years. PMID 19017911. 6. Birks J, Grimley Evans J (2009). Ginkgo biloba for cognitive impairment and dementia. Cochrane Database of Systematic Reviews. Cochrane systematic review of 36 trials. PMID 19160216. 7. Geng J, et al. (2010). Ginseng for cognition. Cochrane Database of Systematic Reviews. Cochrane systematic review. PMID 21154383. 8. Zeng Y, et al. (2024). Effects of ginseng on cognitive function: a systematic review and meta-analysis. Phytotherapy Research. Meta-analysis of 15 RCTs, n=671. doi 10.1002/ptr.8359. 9. Pase MP, et al. (2012). The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials. Journal of Alternative and Complementary Medicine. Systematic review. 10. Kongkeaw C, et al. (2014). Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. Journal of Ethnopharmacology. Meta-analysis. 11. National Center for Complementary and Integrative Health (NCCIH) (2024). Ginkgo and Asian Ginseng: fact sheets for health professionals. Government fact sheets.
It depends entirely which one you mean, which is the whole point of this review. Caffeine has strong, well-established evidence for alertness and attention. The caffeine and l-theanine combination has moderate, real evidence for improved focus. Ginkgo biloba and Asian ginseng have mostly disappointing evidence in their best, largest trials. Bacopa monnieri has a genuine but slow-developing signal for memory. Lumping all of these together under one word obscures a very real evidence gradient.
Caffeine, by a clear margin, though it is rarely marketed with the word "nootropic" because it is too familiar to sound exciting. The European regulatory assessment of caffeine describes it as having the best-substantiated cognitive effects among common nootropic substances, specifically for alertness, attention and vigilance, not for memory or general intelligence, and tolerance develops with regular use.
The best evidence says no. The Ginkgo Evaluation of Memory trial, the largest and longest ginkgo study ever conducted, followed over three thousand adults aged seventy-five and older for a median of six years and found that 120mg of ginkgo taken twice daily did not reduce the incidence of dementia. A separate Cochrane review of thirty-six trials concluded the evidence for any predictable, clinically meaningful cognitive benefit was inconsistent and unreliable.
The evidence is narrow rather than absent. A Cochrane review found a lack of convincing evidence that Panax ginseng enhances cognition in healthy people. A more recent meta-analysis of fifteen trials did find a significant effect on memory specifically, but no benefit for overall cognition, attention or executive function, which is a meaningfully smaller claim than "ginseng boosts brainpower."
It has some of the more credible evidence among traditional herbal nootropics, with research linking it to improved memory acquisition and delayed recall. The honest caveat is timing: benefits typically take around twelve weeks of consistent use to appear, the supporting trials are relatively small and inconsistent in design, and gastrointestinal side effects are common. It is a slow, modest option, not a fast one.
That comparison sits outside what this review can responsibly answer, because racetams and modafinil are prescription or unregulated pharmaceutical substances, not supplements, and using them without medical supervision carries risks this article is not positioned to assess. This review covers ingredients available as supplements with published safety and efficacy data; synthetic cognitive-enhancing drugs are a separate, medical conversation.
Because a long tradition of use, a plausible-sounding mechanism, and a low price point are a persuasive combination even without strong trial support. Traditional use is a reason to study an ingredient, not evidence that it works, and marketing rarely draws that distinction. The gap between how confidently an ingredient is sold and how strong its actual trial evidence is happens to be one of the more consistent patterns in this entire category.
Each carries its own specific caution rather than a single combined answer. Ginkgo has a rare but real bleeding risk and should be stopped before surgery. Ginseng can cause insomnia and has a hypoglycaemia caution, particularly alongside diabetes medication. Caffeine is generally safe within established limits but disrupts sleep late in the day. Stacking several stimulant or bioactive ingredients increases the number of things that can go wrong, so simpler is usually safer.
Because caffeine is too familiar and too cheap to sell as a premium cognitive enhancer, even though the evidence supports it more solidly than almost anything sold under the nootropic label. There is a marketing incentive to promote newer, more exotic-sounding ingredients precisely because they can be sold at a premium, regardless of whether their evidence is any stronger. Familiarity, unfairly, reads as unimpressive.
Because "cognition" is not one thing. Memory, attention and executive function are measured with different tests and can move independently. The more recent meta-analysis found a specific, modest effect on memory tests while finding nothing for attention or executive function, and the earlier Cochrane review, looking at cognition more broadly, found the overall picture unconvincing. Both conclusions can be true simultaneously; the narrower finding is just easier to overlook when a label simply says "supports brain health."
Because the two ingredients are doing entirely different jobs. Caffeine blocks a fatigue-signalling receptor within the hour, which is why its effect is immediate and temporary. Bacopa is studied for its effect on memory formation and retention over time, which by definition cannot be measured, or plausibly produced, in a single sitting. The twelve-week timeline in the trials is not a marketing quirk; it reflects what the studies actually measured.
Scepticism is the right default, not because every ingredient in the category is worthless, but because the word itself carries no evidence requirement. Some ingredients grouped under it, caffeine and the caffeine plus l-theanine combination in particular, hold up well. Others, especially ginkgo in its best trial, do not. The word "nootropic" tells you what a product is claiming, not whether the claim is supported, and those are two very different questions.